Regulus Therapeutics (RGLS) News Today $1.31 +0.04 (+3.15%) Closing price 02/21/2025 04:00 PM EasternExtended Trading$1.34 +0.02 (+1.91%) As of 02/21/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 Time Period Regulus Therapeutics Inc. (RGLS): Among the Cheapest Stocks Insiders Are Buying RecentlyFebruary 21 at 4:37 AM | insidermonkey.comRegulus Therapeutics Inc. (RGLS): Among the Cheapest Stocks Insiders Are Buying RecentlyFebruary 21 at 3:57 AM | msn.comRegulus Therapeutics Inc. (NASDAQ:RGLS) Given Average Recommendation of "Moderate Buy" by AnalystsShares of Regulus Therapeutics Inc. (NASDAQ:RGLS - Get Free Report) have received a consensus recommendation of "Moderate Buy" from the six brokerages that are presently covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a hold recommendation and five have isFebruary 6, 2025 | marketbeat.comRegulus Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences ConferenceFebruary 4, 2025 | prnewswire.comInsiders Give Up US$8.7k As Regulus Therapeutics Stock Drops To US$1.00February 2, 2025 | finance.yahoo.comRegulus Therapeutics Inc. (NASDAQ:RGLS) Director Purchases $20,786.60 in StockFebruary 1, 2025 | insidertrades.comInsider Buying: Joseph Hagan Acquires 50,000 Shares of Regulus Therapeutics Inc (RGLS)January 31, 2025 | gurufocus.comInsider Buying: David Baltimore Acquires Shares of Regulus Therapeutics Inc (RGLS)January 31, 2025 | gurufocus.comDavid Baltimore Buys 19,610 Shares of Regulus Therapeutics Inc. (NASDAQ:RGLS) StockRegulus Therapeutics Inc. (NASDAQ:RGLS - Get Free Report) Director David Baltimore acquired 19,610 shares of the firm's stock in a transaction that occurred on Thursday, January 30th. The shares were bought at an average price of $1.06 per share, for a total transaction of $20,786.60. Following the completion of the purchase, the director now owns 22,169 shares in the company, valued at $23,499.14. This trade represents a 766.31 % increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.January 31, 2025 | marketbeat.comRegulus Therapeutics Inc. (NASDAQ:RGLS) CEO Buys $54,500.00 in StockRegulus Therapeutics Inc. (NASDAQ:RGLS - Get Free Report) CEO Joseph P. Hagan bought 50,000 shares of the company's stock in a transaction that occurred on Thursday, January 30th. The shares were acquired at an average cost of $1.09 per share, with a total value of $54,500.00. Following the transaction, the chief executive officer now owns 260,808 shares in the company, valued at approximately $284,280.72. This represents a 23.72 % increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.January 31, 2025 | marketbeat.comRegulus announces clinical and regulatory updates from its ADPKD programJanuary 31, 2025 | markets.businessinsider.comRegulus Therapeutics Provides Positive Clinical And Regulatory Updates For ADPKD ProgramJanuary 29, 2025 | markets.businessinsider.comRegulus reports progress in ADPKD trial and FDA talksJanuary 29, 2025 | msn.comRegulus stock tumbles 24% amid study, regulatory updatesJanuary 29, 2025 | msn.comRegulus Therapeutics Shares Drop 24% Despite Positive ADPKD Trial DataJanuary 29, 2025 | gurufocus.comRegulus Therapeutics Announces Positive Clinical and Regulatory Updates from its Autosomal Dominant Polycystic Kidney Disease (ADPKD) Program for Farabursen (RGLS8429)January 29, 2025 | prnewswire.comRegulus Therapeutics stock hits 52-week low at $1.16January 28, 2025 | msn.comInsider Selling: Regulus Therapeutics Inc. (NASDAQ:RGLS) Insider Sells 31,445 Shares of StockJanuary 16, 2025 | insidertrades.comInsider Selling: Regulus Therapeutics Inc. (NASDAQ:RGLS) Insider Sells 31,445 Shares of StockRegulus Therapeutics Inc. (NASDAQ:RGLS - Get Free Report) insider Preston Klassen sold 31,445 shares of the firm's stock in a transaction on Monday, January 13th. The shares were sold at an average price of $1.26, for a total value of $39,620.70. Following the completion of the sale, the insider now owns 36,055 shares in the company, valued at approximately $45,429.30. This represents a 46.59 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.January 15, 2025 | marketbeat.comChristopher Ray Aker Sells 38,547 Shares of Regulus Therapeutics Inc. (NASDAQ:RGLS) StockRegulus Therapeutics Inc. (NASDAQ:RGLS - Get Free Report) VP Christopher Ray Aker sold 38,547 shares of the stock in a transaction that occurred on Monday, January 13th. The shares were sold at an average price of $1.26, for a total value of $48,569.22. Following the sale, the vice president now directly owns 54,634 shares of the company's stock, valued at $68,838.84. The trade was a 41.37 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink.January 15, 2025 | marketbeat.comRegulus Therapeutics Inc. (NASDAQ:RGLS) CFO Crispina Calsada Sells 38,716 SharesRegulus Therapeutics Inc. (NASDAQ:RGLS - Get Free Report) CFO Crispina Calsada sold 38,716 shares of the stock in a transaction on Monday, January 13th. The stock was sold at an average price of $1.26, for a total value of $48,782.16. Following the completion of the transaction, the chief financial officer now directly owns 50,566 shares of the company's stock, valued at approximately $63,713.16. The trade was a 43.36 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.January 15, 2025 | marketbeat.comJoseph P. Hagan Sells 115,290 Shares of Regulus Therapeutics Inc. (NASDAQ:RGLS) StockRegulus Therapeutics Inc. (NASDAQ:RGLS - Get Free Report) CEO Joseph P. Hagan sold 115,290 shares of the stock in a transaction that occurred on Monday, January 13th. The shares were sold at an average price of $1.26, for a total value of $145,265.40. Following the completion of the sale, the chief executive officer now directly owns 222,572 shares of the company's stock, valued at approximately $280,440.72. The trade was a 34.12 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.January 15, 2025 | marketbeat.comRegulus Therapeutics Inc. (NASDAQ:RGLS) Receives Average Recommendation of "Moderate Buy" from BrokeragesShares of Regulus Therapeutics Inc. (NASDAQ:RGLS - Get Free Report) have been assigned a consensus recommendation of "Moderate Buy" from the six analysts that are currently covering the stock, Marketbeat.com reports. One equities research analyst has rated the stock with a hold rating and five havJanuary 12, 2025 | marketbeat.comFmr LLC Has $515,000 Stake in Regulus Therapeutics Inc. (NASDAQ:RGLS)Fmr LLC trimmed its holdings in Regulus Therapeutics Inc. (NASDAQ:RGLS - Free Report) by 83.8% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 328,157 shares of the biopharmaceutical company's stock afterDecember 19, 2024 | marketbeat.comRegulus Therapeutics Inc. (NASDAQ:RGLS) Given Consensus Rating of "Moderate Buy" by BrokeragesShares of Regulus Therapeutics Inc. (NASDAQ:RGLS - Get Free Report) have been given an average recommendation of "Moderate Buy" by the six brokerages that are currently covering the stock, Marketbeat reports. One investment analyst has rated the stock with a hold recommendation and five have assigDecember 18, 2024 | marketbeat.comRegulus Therapeutics (NASDAQ:RGLS) Stock Quotes, Forecast and News SummaryDecember 13, 2024 | benzinga.comPoint72 Asset Management L.P. Takes $1.40 Million Position in Regulus Therapeutics Inc. (NASDAQ:RGLS)Point72 Asset Management L.P. bought a new stake in Regulus Therapeutics Inc. (NASDAQ:RGLS - Free Report) in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 893,762 shares of the biopharmaceutical compDecember 11, 2024 | marketbeat.comWith 64% institutional ownership, Regulus Therapeutics Inc. (NASDAQ:RGLS) is a favorite amongst the big gunsDecember 8, 2024 | finance.yahoo.comRA Capital Management L.P. Decreases Position in Regulus Therapeutics Inc. (NASDAQ:RGLS)RA Capital Management L.P. trimmed its position in Regulus Therapeutics Inc. (NASDAQ:RGLS - Free Report) by 87.7% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 766,834 shares of the biopharmaceutical compDecember 5, 2024 | marketbeat.com6,467,802 Shares in Regulus Therapeutics Inc. (NASDAQ:RGLS) Purchased by NEA Management Company LLCNEA Management Company LLC purchased a new position in Regulus Therapeutics Inc. (NASDAQ:RGLS - Free Report) during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm purchased 6,467,802 shares of the biopharmaceutical company's stock, valued at apDecember 1, 2024 | marketbeat.comRegulus Therapeutics Announces Participation at Upcoming Healthcare Investment ConferencesNovember 26, 2024 | prnewswire.comRegulus Therapeutics Inc. (NASDAQ:RGLS) Receives Consensus Rating of "Moderate Buy" from AnalystsShares of Regulus Therapeutics Inc. (NASDAQ:RGLS - Get Free Report) have earned a consensus recommendation of "Moderate Buy" from the six research firms that are currently covering the firm, Marketbeat reports. One investment analyst has rated the stock with a hold recommendation and five have givNovember 23, 2024 | marketbeat.comRegulus Therapeutics Reports Q3 2024 Financial ResultsNovember 22, 2024 | markets.businessinsider.comRA Capital Management's Strategic Reduction in Regulus Therapeutics HoldingsNovember 15, 2024 | gurufocus.comWhat is HC Wainwright's Forecast for RGLS FY2024 Earnings?Regulus Therapeutics Inc. (NASDAQ:RGLS - Free Report) - Investment analysts at HC Wainwright lowered their FY2024 earnings per share (EPS) estimates for shares of Regulus Therapeutics in a note issued to investors on Monday, November 11th. HC Wainwright analyst R. Selvaraju now expects that the bNovember 14, 2024 | marketbeat.comRegulus Therapeutics Poised for Growth: Promising ADPKD Study Results and Strategic Milestones Drive Buy RatingNovember 12, 2024 | markets.businessinsider.comBuy Rating for Regulus Therapeutics Driven by Promising Clinical and Regulatory Prospects for RGLS8429November 12, 2024 | markets.businessinsider.comHC Wainwright Reaffirms Buy Rating for Regulus Therapeutics (NASDAQ:RGLS)HC Wainwright reiterated a "buy" rating and issued a $10.00 price target on shares of Regulus Therapeutics in a research note on Monday.November 11, 2024 | marketbeat.comRegulus Therapeutics Reports Third Quarter 2024 Financial Results and Recent UpdatesNovember 7, 2024 | prnewswire.comPositive Buy Rating for Regulus Therapeutics Driven by Promising Phase 1b Results and Strategic Patent AgreementNovember 1, 2024 | markets.businessinsider.comRegulus Therapeutics (NASDAQ:RGLS) Stock Rating Reaffirmed by HC WainwrightHC Wainwright restated a "buy" rating and issued a $10.00 price target on shares of Regulus Therapeutics in a research report on Wednesday.October 30, 2024 | marketbeat.comRegulus Therapeutics Inc. (NASDAQ:RGLS) Receives Consensus Recommendation of "Moderate Buy" from AnalystsRegulus Therapeutics Inc. (NASDAQ:RGLS - Get Free Report) has been given an average rating of "Moderate Buy" by the six ratings firms that are covering the company, MarketBeat.com reports. One analyst has rated the stock with a hold recommendation and five have issued a buy recommendation on theOctober 29, 2024 | marketbeat.comBuy Rating Affirmed for Regulus Amid Promising miRNA Therapy Advances for ADPKDOctober 10, 2024 | markets.businessinsider.comHC Wainwright Reaffirms "Buy" Rating for Regulus Therapeutics (NASDAQ:RGLS)HC Wainwright restated a "buy" rating and set a $10.00 price objective on shares of Regulus Therapeutics in a report on Tuesday.October 8, 2024 | marketbeat.comRegulus Therapeutics Announces Completion of Enrollment in Fourth Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)October 8, 2024 | prnewswire.comCVI Holdings LLC Cuts Holdings in Regulus Therapeutics Inc. (NASDAQ:RGLS)CVI Holdings LLC decreased its position in Regulus Therapeutics Inc. (NASDAQ:RGLS - Free Report) by 71.5% in the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 401,012 shares of the biopharmaceutical company's stock after selling 1,005,2September 28, 2024 | marketbeat.comStockNews.com Upgrades Regulus Therapeutics (NASDAQ:RGLS) to "Sell"StockNews.com raised shares of Regulus Therapeutics to a "sell" rating in a research note on Tuesday.September 17, 2024 | marketbeat.comRegulus Therapeutics Inc (7RG0.SG)September 16, 2024 | uk.finance.yahoo.comRegulus Therapeutics Announces Participation at Two Healthcare Investment ConferencesAugust 28, 2024 | prnewswire.comVanguard Group Inc. Boosts Holdings in Regulus Therapeutics Inc. (NASDAQ:RGLS)Vanguard Group Inc. boosted its position in shares of Regulus Therapeutics Inc. (NASDAQ:RGLS - Free Report) by 158.4% in the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 740,215 shares of the biopharmaceutical company's stock aftAugust 20, 2024 | marketbeat.com Get Regulus Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for RGLS and its competitors with MarketBeat's FREE daily newsletter. Email Address RGLS Media Mentions By Week RGLS Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. RGLS News Sentiment▼0.660.60▲Average Medical News Sentiment RGLS News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. RGLS Articles This Week▼22▲RGLS Articles Average Week Get Regulus Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for RGLS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies XOMA News Ironwood Pharmaceuticals News Verastem News Vanda Pharmaceuticals News Sangamo Therapeutics News Lexicon Pharmaceuticals News Achieve Life Sciences News Agenus News Dominari News Fortress Biotech News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:RGLS) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredWe recommended Palantir in 2021, now we’re recommending this...I believe it could offer you a MAJOR boost to your retirement. And it pays huge dividends to give you a nic...Behind the Markets | SponsoredBuy NVDA Now? After weeks of volatility, did President Trump just turn Nvidia (NVDA) into a raging BUY? The beloved chip...Chaikin Analytics | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredMarket down? Do this now.During Trump's first term, his tariffs sent gold prices soaring. Investors who acted early made a fortune. Now...Colonial Metals | SponsoredThis Crypto Is Set to Explode in FebruaryIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredElon Takes Aim at Social SecurityElon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Regulus Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Regulus Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free RGLS Stock Alerts